menu
    • menu
    [{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2011","type":"Inapplicable","leadProduct":"Elapegademase","moa":"2'-deoxyadenosine | Adenosine||2\\'-deoxyadenosine | Adenosine","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leadiant Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leadiant Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"Propionylcarnitine","moa":"Amino acid metabolism","graph1":"Immunology","graph2":"Phase III","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leadiant Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leadiant Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"Propionylcarnitine","moa":"Amino acid metabolism","graph1":"Immunology","graph2":"Phase III","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leadiant Biosciences \/ PRA Health Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Leadiant Biosciences \/ PRA Health Sciences"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Peg L asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase I","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leadiant Biosciences \/ Leadiant Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Leadiant Biosciences \/ Leadiant Biosciences"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Chenodeoxycholic Acid","moa":"Bile acid receptor FXR","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Leadiant Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leadiant Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Leadiant Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"DNR","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leadiant Biosciences \/ Leadiant Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Leadiant Biosciences \/ Leadiant Biosciences"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Roneparstat","moa":"heparin derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leadiant Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leadiant Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Thymalfasin","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leadiant Biosciences \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Leadiant Biosciences \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"131-I Tenatumomab","moa":"MUC1","graph1":"Oncology","graph2":"Phase I","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leadiant Biosciences \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Leadiant Biosciences \/ Medpace, Inc"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Leadiant Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRIA","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leadiant Biosciences \/ Leadiant Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Leadiant Biosciences \/ Leadiant Biosciences"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Southern Europe New Drug Organization","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"ST1968","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leadiant Biosciences \/ Southern Europe New Drug Organization","highestDevelopmentStatusID":"6","companyTruncated":"Leadiant Biosciences \/ Southern Europe New Drug Organization"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Piperaquine Tetraphosphate","moa":"Plasmodium falciparum","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leadiant Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leadiant Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Eurartesim","moa":"Plasmodium falciparum heme detoxification \/ DHFR","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leadiant Biosciences \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"6","companyTruncated":"Leadiant Biosciences \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"CPR Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Eurartesim","moa":"Plasmodium falciparum heme detoxification \/ DHFR","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leadiant Biosciences \/ CPR Pharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Leadiant Biosciences \/ CPR Pharma Services"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"CPR Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Eurartesim","moa":"Plasmodium falciparum heme detoxification \/ DHFR","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leadiant Biosciences \/ CPR Pharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Leadiant Biosciences \/ CPR Pharma Services"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"AllianceRx Walgreens","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Partnership","leadProduct":"Cysteamine Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Leadiant Biosciences \/ AllianceRx Walgreens","highestDevelopmentStatusID":"15","companyTruncated":"Leadiant Biosciences \/ AllianceRx Walgreens"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Brigham and Women's Hospital | National Human Genome Research Institute | National Institute of Neurological Disorders and Stroke | National Institute of Arthritis and Musculoskeletal and Skin Diseases | NeuroNext","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"N-Acetyl-D-Mannosamine","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leadiant Biosciences \/ Brigham and Women's Hospital | National Human Genome Research Institute | National Institute of Neurological Disorders and Stroke | National Institute of Arthritis and Musculoskeletal and Skin Diseases | NeuroNext","highestDevelopmentStatusID":"8","companyTruncated":"Leadiant Biosciences \/ Brigham and Women's Hospital | National Human Genome Research Institute | National Institute of Neurological Disorders and Stroke | National Institute of Arthritis and Musculoskeletal and Skin Diseases | NeuroNext"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"STP206","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leadiant Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leadiant Biosciences \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Leadiant Biosciences

    Menu

    Leadiant Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chenodeoxycholic Acid

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (C...

                            Details : Chenodeoxycholic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Xanthomatosis, Cerebrotendinous.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 15, 2024

                            Lead Product(s) : Chenodeoxycholic Acid

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cysteamine Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : AllianceRx Walgreens

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            AllianceRx Walgreens Prime Relaunches Exclusive Partnership for the Distribution of Cystaran® (cysteamine oph...

                            Details : As an exclusive partner, AllianceRx Walgreens Prime is able to offer end-to-end solutions for Leadiant Biosciences and Cystaran patients. Cystaran, a topical ophthalmic therapy for the treatment of corneal cystine crystals in patients with cystinosis.

                            Product Name : Cystaran

                            Product Type : Amino Acid

                            Upfront Cash : Undisclosed

                            March 22, 2022

                            Lead Product(s) : Cysteamine Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : AllianceRx Walgreens

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : N-Acetyl-D-Mannosamine

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Brigham and Women's Hospital | National Human Genome Research Institute | National Institute of Neurological Disorders and Stroke | National Institute of Arthritis and Musculoskeletal and Skin Diseases | NeuroNext

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multi-Center Study of ManNAc for GNE Myopathy

                            Details : ManNAc is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Distal Myopathy, Nonaka Type.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 18, 2020

                            Lead Product(s) : N-Acetyl-D-Mannosamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Brigham and Women's Hospital | National Human Genome Research Institute | National Institute of Neurological Disorders and Stroke | National Institute of Arthritis and Musculoskeletal and Skin Diseases | NeuroNext

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 131-I Tenatumomab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients

                            Details : 131-I Tenatumomab is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            November 11, 2015

                            Lead Product(s) : 131-I Tenatumomab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxytocin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Recipient : Medical University of Vienna

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Chronic Intranasal Oxytocin Administration on Sexual Function in Pre- and Postmenopausal Women

                            Details : Oxytocin is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sexual Dysfunction, Physiological.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            September 01, 2014

                            Lead Product(s) : Oxytocin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Recipient : Medical University of Vienna

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNR

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : University of California, San Diego

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic ...

                            Details : DNR is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 23, 2014

                            Lead Product(s) : DNR

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : University of California, San Diego

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piperaquine Tetraphosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Mal...

                            Details : Piperaquine Tetraphosphate is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Malaria, Falciparum.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            November 25, 2013

                            Lead Product(s) : Piperaquine Tetraphosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STP206

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            STP206 for the Prevention of Necrotizing Enterocolitis (NEC)

                            Details : STP206 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Enterocolitis, Necrotizing.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 01, 2013

                            Lead Product(s) : STP206

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peg L asparaginase

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Dana-Farber Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

                            Details : Pegaspargase is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, T-Cell.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            June 17, 2013

                            Lead Product(s) : Peg L asparaginase

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Dana-Farber Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Leadiant Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roneparstat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SST0001 (Roneparstat) in Advanced Multiple Myeloma

                            Details : Roneparstat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Myeloma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 10, 2013

                            Lead Product(s) : Roneparstat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth